The role of the hypothalamic-pituitary-adrenal axis dysfunction in the pathophysiology of alcohol misuse and suicidal behavior in adolescents

International Journal of Adolescent Medicine and Health

Volumn 19, Issue 1, 2007, Pages 3-9

  Sher, Leo ^a  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

Adolescent; Alcohol; Cortisol; Hypothalamic pituitary adrenal axis; Suicide; Unites States

Indexed keywords

CORTICOSTEROID RECEPTOR; CORTICOTROPIN; GLUCOCORTICOID RECEPTOR; MINERALOCORTICOID RECEPTOR; SEROTONIN 1A RECEPTOR; HYDROCORTISONE; SEROTONIN;

ADOLESCENT; ADOLESCENT HEALTH; ALCOHOLISM; BRAIN FUNCTION; CHILD BEHAVIOR; CHILD PSYCHIATRY; COMORBIDITY; CORTICOTROPIN RELEASE; DISEASE PREDISPOSITION; DRUG MISUSE; DYSPHORIA; ENDOCRINE DISEASE; GENE LOCUS; HIPPOCAMPUS; HUMAN; HYPERACTIVITY; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MAJOR DEPRESSION; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; RISK FACTOR; SEROTONINERGIC SYSTEM; SUICIDAL BEHAVIOR; VULNERABLE POPULATION; AGE; CHILD PSYCHOLOGY; DEPRESSION; HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; PSYCHIATRIC DIAGNOSIS; PSYCHOLOGICAL ASPECT; STATISTICS; SUICIDE;

ADOLESCENT; ADOLESCENT PSYCHOLOGY; AGE FACTORS; ALCOHOLISM; DEPRESSION; DIAGNOSIS, DUAL (PSYCHIATRY); HUMANS; HYDROCORTISONE; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; PITUITARY-ADRENAL SYSTEM; RISK FACTORS; SEROTONIN; SUICIDE;

EID: 34249946179     PISSN: 03340139     EISSN: None     Source Type: Journal    
DOI: 10.1515/IJAMH.2007.19.1.3     Document Type: Review

References (36)

1. Sher L, Zalsman G. Alcohol and adolescent suicide. Int J Adolesc Med Health 2005;17(3):197-203.
2. Miller NS, Mahler JC, Gold MS. Suicide risk associated with drug and alcohol dependence. J Addict Dis 1991;10(3):49-61.
3. Robbins DR, Alessi NE. Suicide and the dexamethasone suppression test in adolescence. Biol Psychiatry 1985; 20:94-119.
4. Sher L, Cooper TB, Mann JJ, Oquendo MA. Modified dexamethasone suppression - corticotropin-releasing hormone stimulation test: a pilot study of young healthy volunteers and implications for alcoholism research in adolescents and young adults. Int J Adolesc Med Health 2006;18(1):133-7.
5. Rivier C. Effect of pretreatment with alcohol on subsequent endocrine and immune responses in the adult male rat. Alcohol Clin Exp Res 1997; 21:1690-4.
6. Lee S, Rivier C. An initial, three-day-long treatment with alcohol induces a long-lasting phenomenon of selective tolerance in the activity of the rat hypothalamic-pituitary-adrenal axis. J Neurosci 1997;17:8856-66.
7. Costa A. Bono G, Martignoni E, Merlo P, Sances G, Nappi. An assessment of hypothalamic-pituitary-adrenal axis functioning in non-depressed, early abstinent alcoholics. Psychoneuroendocrinology 1996;21: 263-75.
8. Rasmussen DD, Boldt BM, Bryant CA, Milton DR, Larsen SA, Wilkinson CW. Chronic daily ethanol and withdrawal: I. Long-term changes in the hypothalamic-pituitary adrenal axis. Alcohol Clin Exp Res 2000; 22:780-801.
9. Gianoulakis C, Krishnan B, Thavundayil J. Enhanced sensitivity of pituitary beta-endorphin to ethanol in subjects at high risk of alcoholism. Arch Gen Psychiatry 1996; 53: 250-7.
10. Zimmermann U, Spring K, Kunz-Ebrecht SR, Uhr M, Wittchen HU, Holsboer F. Effect of ethanol on hypothalamic-pituitary-adrenal system response to psychosocial stress in sons of alcohol-dependent fathers. Neuropsychopharmacology 2004;29:1156-65.
11. Schatzberg AF, Garlow SL, Nemeroff CB. Molecular and cellular mechanisms of depression. In: Davis KL, Charney D, Coyle JT, Nemeroff C, eds. Neuropsychopharmacology: The Fifth Generation of Progress. Philadelphia: Lippincott Williams Wilkins, 2002:1039-50.
12. Thase ME, Howland RH. Biological processes in depression: an updated review and integration. In: Beckham EE, Leber WR, eds. Handbook of depression. New York: Guilford, 1995:213-79.
13. Carroll BJ. The dexamethasone suppression test for melancholia. Br J Psychiatry 1982;140:292-304.
14. Heuser I, Yassouridis A, Holsboer F. The combined dexamethasone/CRH test: a refined laboratory test for psychiatric disorders. J Psychiat Res 1994;28:341-56.
15. Nemeroff CB, Musselman DL, Nathan KI, et al. Pathophysiological basis of psychiatric disorders: focus on mood disrders and schizophrenia. In: Tasman A, Kay J, Lieberman JA, eds. Psychiatry. Philadelphia: WB Saunders, 1997;1:258-95.
16. Holsboer F, Von Bardeleben U, Wiedemann K, Müler OA, Stalla GK. Serial assessment of corticotropin-releasing hormone after dexamethasone in depression - implications for pathophysiology of DST nonsuppression. Biol Psychiatry 1987;22:228-34.
17. Heuser I. The hypothalamo-pituitary-adrenal system in depression. Pharmacopsychiatry 1998;31:10-3.
18. Arana GW, Baldesarini RJ, Ornsteen M. The dexamethasone suppression test for diagnosis and prognosis in psychiatry. Commentary and review. Arch Gen Psychiatry 1985;42:1193-1204.
19. Brown RP, Stoll PM, Stokes PE, Frances A, Sweeney JA, Kocsis JH, Mann JJ. Adrenocortical hyperactivity in depression: effects of agitation, delusions, melancholia, and other illness variables. Psychiatry Res 1987;23:167-78.
20. Thase ME, Howland RH. Biological processes in depression: an updated review and integration. In: Beckham EE, Leber WR, eds. Handbook of depression. New York: Guilford, 1995:213-79.
21. Arana GW, Baldesarini RJ, Ornsteen M. The dexamethasone suppression test for diagnosis and prognosis in psychiatry. Commentary and review. Arch Gen Psychiatry 1985;42:1193-1204.
22. Brown RP, Stoll PM, Stokes PE, Frances A, Sweeney JA, Kocsis JH, Mann JJ. Adrenocortical hyperactivity in depression: effects of agitation, delusions, melancholia, and other illness variables. Psychiatry Res 1987; 23:167-178.
23. Oquendo MA, Echavarria G, Galfalvy HC, Grunebaum MF, Burke A, Barrera A, Cooper TB, Malone KM, Mann JJ. Lower cortisol levels in depressed patients with comorbid post traumatic stress disorder. Neuropsychopharmacology 2003;28(3)591-8.
24. Mendlewicz J, Charles G, Franckson JM. The dexamethasone suppression test in affective disorder: relationships to clinical and genetic subgroups. Br J Psychiatry 1982;141:464-70.
25. Lester D. The dexamethasone suppression test as an indicator of suicide: a meta-analysis. Pharmacopsychiatry 1995;25:265-70.
26. Träskman-Bendz L, Ekman R, Regnell G, Öhman R. HPA-related CSF neuropeptides in suicide attempters. Eur Neuropsychopharmacol 1992;2: 99-106.
27. Meltzer HY, Perline R, Tricou BJ, Lowy M, Robertson A. Effect of 5-hydroxytryptophan on serum cortisol levels in major affective disorders. II. Relation to suicide, psychosis and depressive symptoms. Arch Gen Psychiatry 1984;41:379-87.
28. Coryell W, Schlesser M. The dexamethasone suppression test and suicide prediction. Am J Psychiatry 2001;158:748-53.
29. Brunner J, Stalla GK, Stalla J, Uhr M, Grabner A, Wetter TC et al. Decreased corticotropin-releasing hormone (CRH) concentrations in the cerebrospinal fluid of eucortisolemic suicide attempters. J Psychiatr Res 2001;35:1-9.
30. Young EA, Coryell W. Suicide and the hypothalamic-pituitary-adrenal axis. Lancet 2005;366(9490):959-61.
31. Zimmerman M, Coryell W, Pfohl B. The validity of the dexamethasone suppression test as a marker for endogenous depression. Arch Gen Psychiatry 1986;43:347-55.
32. Norman WH, Brown WA, Miller IW, Keitner GI, Overholser JC. The dexamethasone suppression test and completed suicide. Acta Psychiatr Scand 1990;81:120-5.
33. Joëls M, De Kloet ER. Coordinative mineralocorticoid and glucocorticoid receptor-mediated control of responses to serotonin in rat hippocampus. Neuroendocrinology 1992;55:344-50.
34. Lopez JF, Chalmers DT, Little KY, Watson SJ. Regulation of serotonin1A, glucocorticoid, and mineralocorticoid receptor in rat and human hippocampus: Implications for the neurobiology of depression. Biol Psychiatry 1998;43:547-73.
35. Sheline YI, Wang PW, Gado MH, Csernansky JG, Vannier MW. Hippocampal, atrophy in recurrent major depression. Proc Natl Acad Sci USA 1996;93:3908-13.
36. Sher L, Mann JJ. Neurobiology of suicide. In: Soares JC, Gershon S, eds. Textbook of medical psychiatry. New York: Marcel Dekker. 2003:701-11.